Milestone-Heavy Deals Shift Cancer Drug Risk
Biotech developers and healthcare partners should note how up-front payments are giving way to milestone-based structures in early oncology licensing.
Updated on Nov. 19, 2026 in Healthcare

AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Germany-based private biotech Disco Pharmaceuticals, with Disco receiving $40 million upfront. The early-stage deal focuses on AND-gated bispecific therapies for solid tumors, a category of drugs that would be developed globally.
Why it matters
The structure lets big drugmakers buy access to early-stage cancer platforms without paying full development costs up front, shifting risk to milestone payments that are only triggered if programs advance. It reflects a continued pattern of large pharma leaning on smaller biotechs for novel mechanisms in oncology.
The deal carries a $40 million upfront payment and up to $2.5 billion in milestones, plus tiered royalties on worldwide net sales. AbbVie's January upfront payment of $650 million to RemeGen for comparable solid-tumor bispecific rights outside China gives a reference point for how the company is pricing early oncology platforms.
The players
AbbVie
A large global biopharmaceutical company with a broad oncology and immunology portfolio, which uses licensing deals to extend its late-stage pipeline.
Disco Pharmaceuticals
A privately held German biotech developing AND-gated bispecific therapies for solid tumors at an early research stage.
RemeGen
A China-based biopharmaceutical company that licensed bispecific rights outside China to AbbVie in January.
The details
Disco's therapies are designed to recognize cancer cells only when two target proteins are present at the same time, which the company hopes will spare healthy tissue. Disco will handle research and discovery, while AbbVie gets the right to exclusively license selected programs for further development once Disco completes specified research. Disco has been developing these AND-gated approaches for small-cell lung and colorectal cancer.
Timeline
January: AbbVie paid RemeGen $650 million upfront for bispecific rights outside China.
November 19, 2026: Disco announced the AbbVie deal on Thursday.
Second half of next year: Disco expects to select a development candidate.
Market Landscape
AbbVie's January $650 million upfront payment to RemeGen set a recent benchmark for solid-tumor bispecific deals, and this agreement extends the same strategy to earlier-stage discovery. Large drugmakers increasingly use milestone-heavy structures to access novel cancer mechanisms from smaller biotechs.
Operators in healthcare services and life-sciences supply should watch for more milestone-based licensing structures, which can shift development risk and affect how partners price early-stage work. Companies evaluating their own pipeline or partnership strategy should consult qualified counsel on deal terms, royalty structures, and licensing rights.
The takeaway
The key operating insight is that large pharma is increasingly buying early oncology optionality rather than waiting for late-stage assets. Healthcare operators should track whether Disco's development candidate selection in the second half of next year triggers further milestone or licensing activity.
What happens next
Disco is expected to select a development candidate in the second half of next year, which will be the next concrete signal of whether the collaboration moves toward clinical development.
Further reading
For broader context on how drug pipelines are built through partnerships, explore our Healthcare coverage.


